https://orcid.org/0000-0002-5829-107X
References
- Sheng Z, Song S, Yu M, et al. Comparison of acalabrutinib plus obinutuzumab, ibrutinib plus obinutuzumab and venetoclax plus obinutuzumab for untreated CLL: a network meta-analysis. Leuk Lymphoma. 2020. DOI:10.1080/10428194.2020.1811271
- Messori A. The advantages of restricted mean survival time in analysing Kaplan-Meier survival curves: analysis of 55 articles published in the last 12 months. Open Science Framework; [cited 2020 Jul 6]. Available from: https://osf.io/365br/
- Uno H, Tian L, Horiguchi M, et al. Package ≪survRM2≫, June 13, 2020; [cited 2020 Aug 1]. Available from: https://cran.r-project.org/web/packages/survRM2/survRM2.pdf.
- Messori A, Trippoli S, Vaiani M, et al. Survival meta-analysis of individual patient data and survival meta-analysis of published (aggregate) data – is there an intermediate approach between these two opposite options? Clin Drug Invest. 2000;20(5):309–331.
- Cumming G, Finch S. Inference by eye: confidence intervals and how to read pictures of data. Am Psychol. 2005;60:170–180.